Epidermal growth factor receptor (EGFR) signaling in the tissue around oral cancers both increases nerve sensitivity and makes opioids less effective. The findings point to a shared mechanism underlying both oral cancer pain ...
Jan 27, 2026
0
7
Some lung cancers manage to overcome a targeted drug therapy despite it showing initial success. Yale researchers have now discovered a molecular-level resistance mechanism that begins to take hold as early as six to eight ...
Nov 19, 2025
0
9
KRAS mutations are among the most common genetic alterations in cancer and are considered particularly difficult to treat. In colon cancer, the second most common cause of cancer death, such mutations severely limit therapeutic ...
May 26, 2025
0
33
A team led by Mount Sinai researchers has identified stem cell populations and mechanisms underlying age-related degeneration in glands that are vital to eye function. The findings, published in Nature Communications on February ...
Feb 24, 2025
0
23
Receptor protein tyrosine phosphatases are cell membrane-localized proteins. They are regulators of cell-cell contacts and are also considered likely to be tumor suppressors, but the specifics of how they function are unknown. ...
Jul 24, 2024
0
33
A new study, led by Prof. Liu from the department of pharmacy, University of Electronic Science and Technology of China, discovered that the extracellular cell matrix (ECM) could induce the drug resistance of breast cancer ...
Apr 8, 2024
0
44
The Organoid group at the Hubrecht Institute has identified a new link between FBXW7 mutations and epidermal growth factor receptor (EGFR) signaling activity. The FBXW7 gene is commonly mutated in colorectal cancer and such ...
Mar 18, 2024
0
39
Many cancer cells never leave their original tumors. Some cancer cells evolve the ability to migrate to other tissues, but once there cannot manage to form new tumors, and so remain dormant. The deadliest cancer cells are ...
Jan 5, 2023
0
71
Researchers at VCU Massey Cancer Center discovered a cellular partnership that drives the growth of deadly brain tumors and could potentially serve as a novel target for disease treatment.
Oct 5, 2022
0
71
The multitargeted tyrosine kinase inhibitor (MKI), lenvatinib, is widely used to treat advanced and metastatic thyroid cancer. However, the molecular mechanisms by which thyroid cancer cells become resistant to lenvatinib ...
Sep 13, 2022
0
62
